BNTX Sep 2024 92.500 put
| Previous close | 6.06 |
| Open | 6.06 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 92.50 |
| Expiry date | 2024-09-20 |
| Day's range | 6.06 - 6.06 |
| Contract range | N/A |
| Volume | |
| Open interest | 63 |
Globe NewswireBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi
- Thomson Reuters StreetEvents
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call
BenzingaEuropean Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing legal battle with Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) over the Covid-19 vaccine. The EPO’s Opposition Division upheld the validity of one of Moderna’s crucial patents, boosting the mRNA vaccine maker’s efforts to reclaim pandemic profits from its competitors, the Financial Times reports. Although Pfizer has nine months to appeal the decision, the EPO’s writte
